{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:24:15Z","timestamp":1791923055746,"version":"4.3.4"},"reference-count":94,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Bladder cancer remains one of the most common malignancies of the urinary tract. Although the treatment landscape has expanded rapidly in recent years, gemcitabine still occupies a central position in intravesical treatment for non-muscle-invasive bladder cancer, in perioperative systemic therapy for muscle-invasive disease, and in platinum-based first-line regimens for advanced urothelial carcinoma. Yet the long-term benefit of gemcitabine is frequently curtailed by primary non-response or acquired resistance. In practice, this problem is often recognized only after radiographic progression or clear clinical deterioration has occurred. This review summarizes recent progress in bladder cancer therapy and translational research, with a particular emphasis on the biological basis and hierarchical evolution of gemcitabine resistance. We establish a 3-stage operational model of resistance, distinguishing: (1) early pharmacologic resistance driven by impaired drug uptake\/activation or enhanced inactivation; (2) intermediate resistance driven by enhanced DNA damage repair, replication stress tolerance, and pro-survival autophagy signaling; and (3) late adaptive resistance driven by epithelial-mesenchymal transition (EMT), stemness maintenance, metabolic reprogramming, non-coding RNA-mediated epigenetic regulation, inflammatory microenvironmental remodeling, and extracellular vesicle-based intercellular transmission. These layers function as an interactive network, with sequential emergence under treatment pressure and parallel activation in context-dependent clinical settings. We stratify key mechanistic nodes (including the HYAL4-V1\/CD44\/JAK2-STAT3\/CDA axis, AKR1C3, AP1M2-RAD54B, PRPF19-DDB1, AKT\/mTOR signaling, Beclin-1-dependent autophagy, the MINCR\/ZEB1\/PHGDH axis, and IL-6-associated inflammatory states) by their clinical evidence quality and translational readiness, explicitly distinguishing preclinical discovery from clinically validated findings. Critically, most mechanistic findings remain at the preclinical or retrospective validation stage, with no markers yet approved for routine clinical use. Future work must prioritize longitudinal paired clinical samples, standardized analytic assays for dynamic biomarkers, and the integration of functional models (organoids, microfluidic systems), multi-omics technologies (single-cell sequencing, spatial transcriptomics), and liquid-biopsy approaches to translate mechanistic discoveries into clinically actionable predictive tools and therapeutic strategies.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1860957","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T06:58:40Z","timestamp":1780037920000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Ming","family":"Jin","sequence":"first","affiliation":[{"name":"Heilongjiang University of Chinese Medicine","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Cai","sequence":"additional","affiliation":[{"name":"Qiqihar Medical University","place":["Qiqihar, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Bu","sequence":"additional","affiliation":[{"name":"Qiqihar Medical University","place":["Qiqihar, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jicheng","family":"Liu","sequence":"additional","affiliation":[{"name":"Qiqihar Medical University","place":["Qiqihar, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Heilongjiang University of Chinese Medicine","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: A review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41571-023-00744-3","article-title":"Global trends in the epidemiology of bladder cancer: Challenges for public health and clinical practice","volume":"20","author":"van Hoogstraten","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01188-6","article-title":"Current best practice for bladder cancer: A narrative review of diagnostics and treatments","volume":"400","author":"Comp\u00e9rat","year":"2022","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21631","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020","volume":"70","author":"Patel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2025 guidelines","volume":"87","author":"van der Heijden","year":"2025","journal-title":"Eur Urol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02568-1","article-title":"Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: A phase 2 trial","volume":"29","author":"Galsky","year":"2023","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.06.014","article-title":"Long-term outcomes from a phase 2 study of neoadjuvant chemotherapy for muscle-invasive bladder cancer (SWOG S1314; NCT02177695)","volume":"84","author":"Flaig","year":"2023","journal-title":"Eur Urol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.annonc.2023.09.3116","article-title":"Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer","volume":"35","author":"Catto","year":"2024","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2020.1782201","article-title":"The emerging role of antibody-drug conjugates in urothelial carcinoma","volume":"20","author":"Lattanzi","year":"2020","journal-title":"Expert Rev Anticancer Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/03915603221139907","article-title":"Management of metastatic urothelial carcinoma: current approach, emerging agents, and future perspectives","volume":"90","author":"Iacovelli","year":"2023","journal-title":"Urologia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000942","article-title":"Evolving systemic management of urothelial cancers","volume":"35","author":"Tan","year":"2023","journal-title":"Curr Opin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1038\/s41467-023-37696-2","article-title":"Bladder cancer organoids as a functional system to model different disease stages and therapy response","volume":"14","author":"Minoli","year":"2023","journal-title":"Nat Commun"},{"key":"B15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.5213\/inj.2448198.099","article-title":"Advances in liquid biopsy for diagnosis of bladder cancer","volume":"28","author":"Seok","year":"2024","journal-title":"Int Neurourol J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00280-022-04459-7","article-title":"An update on antibody-drug conjugates in urothelial carcinoma: state of the art strategies and what comes next","volume":"90","author":"D'Angelo","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1177\/11795549241290787","article-title":"The role of antibody-drug conjugates in urothelial cancer: a review of recent advances in the treatment of locally advanced and metastatic urothelial cancer","volume":"18","author":"Vlachou","year":"2024","journal-title":"Clin Med Insights Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"v7","DOI":"10.1093\/annonc\/mdj941","article-title":"Cellular pharmacology of gemcitabine","author":"Mini","year":"2006","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/s1368-7646(02)00002-x","article-title":"Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine)","volume":"5","author":"Bergman","year":"2002","journal-title":"Drug Resist Update"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402114","article-title":"Nucleoside analogues: Mechanisms of drug resistance and reversal strategies","volume":"15","author":"Galmarini","year":"2001","journal-title":"Leukemia"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2020.39","article-title":"Attempts to remodel the pathways of gemcitabine metabolism: Recent approaches to overcoming tumours with acquired chemoresistance","volume":"3","author":"Saiki","year":"2020","journal-title":"Cancer Drug Resist"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.11.026","article-title":"The emerging role of cytidine deaminase in human diseases: A new opportunity for therapy","volume":"28","author":"Frances","year":"2020","journal-title":"Mol Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers2042044","article-title":"Human equilibrative nucleoside transporter 1 (hENT1) in pancreatic adenocarcinoma: Towards individualized treatment decisions","volume":"2","author":"Spratlin","year":"2010","journal-title":"Cancers (Basel)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i26.8482","article-title":"hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: A systematic review","volume":"20","author":"Nordh","year":"2014","journal-title":"World J Gastroenterol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.09.067","article-title":"Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer","volume":"136","author":"Farrell","year":"2009","journal-title":"Gastroenterology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.18.00240","article-title":"Predictive and prognostic properties of human equilibrative nucleoside transporter 1 expression in gemcitabine-treated pancreatobiliary cancer: A meta-analysis","volume":"3","author":"Vos","year":"2019","journal-title":"Jco Precis Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v27.i40.6844","article-title":"Role of human nucleoside transporters in pancreatic cancer and chemoresistance","volume":"27","author":"Carter","year":"2021","journal-title":"World J Gastroenterol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1021\/jm401853a","article-title":"Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development","volume":"57","author":"Slusarczyk","year":"2014","journal-title":"J Med Chem"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2016.08.021","article-title":"Recent advances in drug delivery strategies for improved therapeutic efficacy of gemcitabine","volume":"93","author":"Dubey","year":"2016","journal-title":"Eur J Pharm Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2174\/0929867326666190816230650","article-title":"Small molecular gemcitabine prodrugs for cancer therapy","volume":"27","author":"Miao","year":"2020","journal-title":"Curr Med Chem"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0244-1","article-title":"Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study","volume":"119","author":"Blagden","year":"2018","journal-title":"Br J Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00274","article-title":"Natural history and genomic landscape of chemotherapy-resistant muscle-invasive bladder cancer","volume":"8","author":"Lenis","year":"2024","journal-title":"Jco Precis Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0422","article-title":"HYAL4-V1\/Chondroitinase (Chase) drives gemcitabine resistance and predicts chemotherapy failure in patients with bladder cancer","volume":"27","author":"Hasanali","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41420-022-01242-8","article-title":"Stepwise molecular mechanisms responsible for chemoresistance in bladder cancer cells","volume":"8","author":"Mun","year":"2022","journal-title":"Cell Death Discov"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202500423R","article-title":"AP1M2 drives gemcitabine-cisplatin chemoresistance by enhancing RAD54B-associated DNA repair in bladder cancer","volume":"39","author":"Liu","year":"2025","journal-title":"FASEB J"},{"key":"B36","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s10616-023-00599-7","article-title":"PRPF19 functions in DNA damage repair and gemcitabine sensitivity via regulating DDB1 in bladder cancer cells","volume":"76","author":"Yu","year":"2024","journal-title":"Cytotechnology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-01634-z","article-title":"KNSTRN promotes tumorigenesis and gemcitabine resistance by activating AKT in bladder cancer","volume":"40","author":"Xiong","year":"2021","journal-title":"Oncogene"},{"key":"B38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3892\/or.2021.8244","article-title":"Berberine enhances gemcitabine-induced cytotoxicity in bladder cancer by downregulating Rad51 expression through inactivating the PI3K\/Akt pathway","volume":"47","author":"Gao","year":"2022","journal-title":"Oncol Rep"},{"key":"B39","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/s41419-025-08368-4","article-title":"TPI1 enhances gemcitabine resistance in bladder cancer by promoting autophagy through activating Beclin-1","volume":"16","author":"Wang","year":"2025","journal-title":"Cell Death Dis"},{"key":"B40","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s10735-025-10510-7","article-title":"Long non-coding RNA MINCR silencing contributes to suppressed gemcitabine resistance in bladder cancer by blocking the ZEB1\/PHGDH axis through microRNA-876-5p up-regulation","volume":"56","author":"Xu","year":"2025","journal-title":"J Mol Histol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.70179","article-title":"Extracellular vesicle-mediated regulation of H3C14 contributes to gemcitabine resistance in bladder cancer","volume":"14","author":"Huang","year":"2025","journal-title":"J Extracell Vesicles"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2023.110840","article-title":"Inhibition of aldo-keto reductase 1C3 overcomes gemcitabine\/cisplatin resistance in bladder cancer","volume":"388","author":"Himura","year":"2024","journal-title":"Chem Biol Interact"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3739","article-title":"Bladder cancer cell-intrinsic PD-L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy","volume":"10","author":"Zhang","year":"2021","journal-title":"Cancer Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2021.1992384","article-title":"Emerging roles of autophagy in the development and treatment of urothelial carcinoma of the bladder","volume":"25","author":"Gupta","year":"2021","journal-title":"Expert Opin Ther Targets"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1177\/1535370220959336","article-title":"Contrast effects of autophagy in the treatment of bladder cancer","volume":"246","author":"Konac","year":"2021","journal-title":"Exp Biol Med (Maywood)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17796","article-title":"HMGB1-mediated autophagy attenuates gemcitabine-induced apoptosis in bladder cancer cells involving JNK and ERK activation","volume":"8","author":"Yin","year":"2017","journal-title":"Oncotarget"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2018.4376","article-title":"Hypoxia-induced autophagy promotes gemcitabine resistance in human bladder cancer cells through hypoxia-inducible factor 1\u03b1 activation","volume":"53","author":"Yang","year":"2018","journal-title":"Int J Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2020.8856","article-title":"Oblongifolin C reverses GEM resistance via suppressing autophagy flux in bladder cancer cells","volume":"20","author":"Huang","year":"2020","journal-title":"Exp Ther Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0254011","article-title":"Gemcitabine-induced Gli-dependent activation of hedgehog pathway resists to the treatment of urothelial carcinoma cells","volume":"16","author":"Chang","year":"2021","journal-title":"PLoS One"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10051162","article-title":"Targeted inhibition of O-linked \u03b2-N-acetylglucosamine transferase as a promising therapeutic strategy to restore chemosensitivity and attenuate aggressive tumor traits in chemoresistant urothelial carcinoma of the bladder","volume":"10","author":"Lee","year":"2022","journal-title":"Biomedicines"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13684","article-title":"Targeting metabolic reprogramming to overcome drug resistance in advanced bladder cancer: Insights from gemcitabine- and cisplatin-resistant models","volume":"18","author":"Kawahara","year":"2024","journal-title":"Mol Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.117182","article-title":"Targeting BACH1\/PSPH axis suppresses bladder cancer progression and gemcitabine resistance by downregulating S100A2 expression","volume":"241","author":"Ma","year":"2025","journal-title":"Biochem Pharmacol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.7150\/thno.102730","article-title":"DLGAP5 enhances bladder cancer chemoresistance by regulating glycolysis through MYC stabilization","volume":"15","author":"Deng","year":"2025","journal-title":"Theranostics"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153782","article-title":"NXPH4 promotes gemcitabine resistance in bladder cancer by enhancing reactive oxygen species and glycolysis activation through modulating NDUFA4L2","volume":"14","author":"Wang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B55","doi-asserted-by":"publisher","first-page":"41610","DOI":"10.1038\/s41598-025-25534-y","article-title":"Tumor-derived lactate fuels the STAT3-LCN2 pathway to promote bladder cancer Malignancy and chemoresistance","volume":"15","author":"Yu","year":"2025","journal-title":"Sci Rep"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1656","article-title":"Long noncoding RNA LBCS inhibits self-renewal and chemoresistance of bladder cancer stem cells through epigenetic silencing of SOX2","volume":"25","author":"Chen","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13192","article-title":"microRNA-99a-5p induces cellular senescence in gemcitabine-resistant bladder cancer by targeting SMARCD1","volume":"16","author":"Tamai","year":"2022","journal-title":"Mol Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03873-8","article-title":"Long non-coding RNA GHET1 contributes to chemotherapeutic resistance to gemcitabine in bladder cancer","volume":"84","author":"Li","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgad065","article-title":"Construction and identification of lncRNA\/circRNA-coregulated ceRNA networks in gemcitabine-resistant bladder carcinoma","volume":"44","author":"Pan","year":"2023","journal-title":"Carcinogenesis"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-04032-y","article-title":"Circular RNAs: Driving forces behind chemoresistance and immune evasion in bladder cancer","volume":"398","author":"Saadh","year":"2025","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.672679","article-title":"Role of long non-coding RNAs on bladder cancer","volume":"9","author":"Li","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1080\/07357907.2022.2146703","article-title":"Long non-coding RNA and chemoresistance in bladder cancer - a mini review","volume":"41","author":"Lima","year":"2023","journal-title":"Cancer Invest"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115242","article-title":"Molecular landscape of lncRNAs in bladder cancer: from drug resistance to novel lncRNA-based therapeutic strategies","volume":"165","author":"Mehmandar-Oskuie","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B64","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.canlet.2016.08.015","article-title":"Long non-coding RNA UCA1 promotes cisplatin\/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells","volume":"382","author":"Pan","year":"2016","journal-title":"Cancer Lett"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.809620","article-title":"Gemcitabine-resistant biomarkers in bladder cancer are associated with tumor-immune microenvironment","volume":"9","author":"Song","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2022.05.020","article-title":"Serum IL-6 level is associated with clinical outcome of intravesical gemcitabine therapy in T1 non-muscle-invasive bladder cancer","volume":"40","author":"Tong","year":"2022","journal-title":"Urol Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052744","article-title":"Extracellular vesicles as biomarkers carriers in bladder cancer: diagnosis, surveillance, and treatment","volume":"22","author":"Georgantzoglou","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19092822","article-title":"Extracellular vesicles in bladder cancer: biomarkers and beyond","volume":"19","author":"Liu","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076757","article-title":"Extracellular vesicles as potential bladder cancer biomarkers: take it or leave it","volume":"24","author":"Teixeira-Marques","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251349288","article-title":"Extracellular vesicles-derived extracellular RNA in bladder cancer: current progress and future prospects","volume":"17","author":"Chen","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-023-00725-2","article-title":"Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease","volume":"20","author":"Rose","year":"2023","journal-title":"Nat Rev Urol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-471912","article-title":"Current and future role of circulating DNA in the diagnosis and management of urothelial carcinoma","volume":"45","author":"Bellmunt","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B73","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41585-025-01023-9","article-title":"Circulating tumour DNA and circulating tumour cells in bladder cancer - from discovery to clinical implementation","volume":"22","author":"Lindskrog","year":"2025","journal-title":"Nat Rev Urol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2025.06.009","article-title":"Urinary tumor DNA-based liquid biopsy in bladder cancer management: a systematic review","volume":"11","author":"Lee","year":"2025","journal-title":"Eur Urol Focus"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf409","article-title":"Multidimensional liquid biopsy in bladder cancer: advances in circulating tumor cells, circulating tumor DNA, exosomes, and metabolomics","volume":"31","author":"Zeng","year":"2026","journal-title":"Oncologist"},{"key":"B76","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s40164-024-00579-3","article-title":"Prospective pharmacotyping of urothelial carcinoma organoids for drug sensitivity prediction - feasibility and real world experience","volume":"13","author":"Melzer","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.cell.2018.03.017","article-title":"Tumor evolution and drug response in patient-derived organoid models of bladder cancer","volume":"173","author":"Lee","year":"2018","journal-title":"Cell"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13219","article-title":"Bladder organoids and spheroids: potential tools for normal and diseased tissue modelling","volume":"39","author":"Vasyutin","year":"2019","journal-title":"Anticancer Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092062","article-title":"Patient-derived bladder cancer organoid models in tumor biology and drug testing: a systematic review","volume":"14","author":"Medle","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2022.07.006","article-title":"Bladder cancer patient-derived organoids and avatars for personalized cancer discovery","volume":"8","author":"Kim","year":"2022","journal-title":"Eur Urol Focus"},{"key":"B81","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.euf.2024.08.008","article-title":"Patient-derived organoids in bladder cancer: opportunities and challenges","volume":"11","author":"Radi\u0107","year":"2025","journal-title":"Eur Urol Focus"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2023.1302983","article-title":"Prediction of anticancer drug resistance using a 3D microfluidic bladder cancer model combined with convolutional neural network-based image analysis","volume":"11","author":"Tak","year":"2024","journal-title":"Front Bioeng Biotechnol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s42003-024-06426-9","article-title":"Digital spatial profiling of the microenvironment of muscle invasive bladder cancer","volume":"7","author":"Eyers","year":"2024","journal-title":"Commun Biol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1522582","article-title":"Spatially-resolved analyses of muscle invasive bladder cancer microenvironment unveil a distinct fibroblast cluster associated with prognosis","volume":"15","author":"Feng","year":"2024","journal-title":"Front Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2022.12.003","article-title":"A phase 1\/2 study of rapamycin and cisplatin\/gemcitabine for treatment of patients with muscle-invasive bladder cancer","volume":"21","author":"Makrakis","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3390\/nu16050623","article-title":"Sulforaphane inhibits adhesion and migration of cisplatin- and gemcitabine-resistant bladder cancer cells in vitro","volume":"16","author":"Xie","year":"2024","journal-title":"Nutrients"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.21037\/tau-2025-383","article-title":"Ursolic acid sensitizes bladder cancer to gemcitabine chemotherapy by concurrently targeting PI3K\/AKT and JNK pathways","volume":"14","author":"Huang","year":"2025","journal-title":"Transl Androl Urol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-7234-0_23","article-title":"Targeting the PI3K\/AKT\/mTOR pathway in bladder cancer","volume":"1655","author":"Sathe","year":"2018","journal-title":"Methods Mol Biol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2017.10.011","article-title":"The current status and future role of the phosphoinositide 3 kinase\/AKT signaling pathway in urothelial cancer: an old pathway in the new immunotherapy era","volume":"16","author":"Liu","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14061555","article-title":"Emerging roles for mammalian target of rapamycin (mTOR) complexes in bladder cancer progression and therapy","volume":"14","author":"Huan","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2010.133","article-title":"Expanding therapeutic targets in bladder cancer: the PI3K\/Akt\/mTOR pathway","volume":"90","author":"Ching","year":"2010","journal-title":"Lab Invest"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-024-03136-8","article-title":"Engineered targeting OIP5 sensitizes bladder cancer to chemotherapy resistance via TRIP12-PPP1CB-YBX1 axis","volume":"43","author":"Wang","year":"2024","journal-title":"Oncogene"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1002\/2211-5463.13616","article-title":"Characterization and treatment of gemcitabine- and cisplatin-resistant bladder cancer cells with a pan-RAS inhibitor","volume":"13","author":"Yoshino","year":"2023","journal-title":"FEBS Open Bio"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.kjms.2014.03.004","article-title":"Involvement of p38 mitogen-activated protein kinase in acquired gemcitabine-resistant human urothelial carcinoma sublines","volume":"30","author":"Kao","year":"2014","journal-title":"Kaohsiung J Med Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1860957\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T06:58:42Z","timestamp":1780037922000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1860957\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":94,"alternative-id":["10.3389\/fimmu.2026.1860957"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1860957","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"article-number":"1860957"}}